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Abstract  116 
Objective: This study aims to determine whether congenital arhinia/Bosma arhinia 117 
microphthalmia syndrome (BAMS) and facioscapulohumeral muscular dystrophy type 2 118 
(FSHD2), two seemingly unrelated disorders both caused by heterozygous pathogenic 119 
missense variants in the SMCHD1 gene, might represent different ends of a broad single 120 
phenotypic spectrum associated with SMCHD1 dysfunction. 121 
Methods: We examined and/or interviewed 14 FSHD2 patients and 4 unaffected family 122 
members with N-terminal SMCHD1 pathogenic missense variants to identify BAMS sub-123 
phenotypes. 124 
Results: None of the FSHD2 patients or family members demonstrated any congenital defects 125 
or dysmorphic features commonly found in patients with BAMS. One patient became 126 
anosmic after nasal surgery and one patient was hyposmic; one man was infertile (unknown 127 
cause) but reported normal pubertal development. 128 
Conclusions: These data suggest that arhinia/BAMS and FSHD2 do not represent one 129 
phenotypic spectrum and that SMCHD1 pathogenic variants by themselves are insufficient to 130 
cause either of the two disorders. More likely, both arhinia/BAMS and FSHD2 are caused by 131 
complex oligogenic or multifactorial mechanisms which only partially overlap at the level of 132 
SMCHD1. 133 
 134 
135 
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Introduction 136 
Identical pathogenic variants in the ‘structural maintenance of chromosomes flexible hinge 137 
domain containing 1’ (SMCHD1) gene are associated with two seemingly unrelated disorders: 138 
facioscapulohumeral muscular dystrophy type 2 (FSHD2)1, a rare form of adult onset 139 
muscular dystrophy, and arhinia, a severe congenital malformation often accompanied by 140 
reproductive and ocular defects, a triad called Bosma arhinia microphthalmia syndrome 141 
(BAMS).2-4 142 
FSHD2 has a complex etiology that involves SMCHD1 (18p11.32) and the D4Z4 143 
macrosatellite repeat array (4q35).1 Loss of SMCHD1 repressive activity leads to partial 144 
relaxation of the D4Z4 chromatin structure and de-repression of the normally suppressed 145 
DUX4 retrogene in the D4Z4 unit. Only specific 4q35 haplotypes provide a poly-adenylation 146 
signal (DUX4PAS) that stabilizes the DUX4 mRNA, permitting translation of the myotoxic 147 
DUX4 protein.1, 5 Contraction of the D4Z4 repeat array to 1-10 units can also relax the D4Z4  148 
locus and de-repress DUX4 expression; this is the mechanism underlying the more common 149 
form of FSHD called FSHD type 1 (FSHD1).5 150 
In contrast to FSHD2, where missense and loss-of-function variants are distributed along the 151 
entire SMCHD1 locus, in BAMS patients, the variants are all missense and clustered within or 152 
immediately downstream of the ATPase domain.2, 3 While D4Z4 hypomethylation akin to 153 
FSHD2 in BAMS patients suggests a loss-of-function mechanism2, a gain of function mode of 154 
action has also been proposed.3  155 
To date, only one patient with both arhinia and FSHD2 and one multiplex family with both 156 
conditions have been reported.2 There has yet to be a systematic investigation of BAMS-157 
associated features in FSHD2 patients. Therefore, we performed phenotypic and genotypic 158 
studies in FSHD2 patients and their family members with pathogenic missense variants in the 159 
N-terminal region of SMCHD1 to identify potential areas of overlap. 160 
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 161 
Materials and methods 162 
Patients 163 
We identified 23 FSHD patients with heterozygous pathogenic missense variantsnear the 164 
ATPase domain of SMCHD1 in the FSHD genetic database in the Human Genetics 165 
department of the Leiden University Medical Center. Family members of one patient were 166 
recruited through a cohort-study (FSHD-FOCUS study) by the Neurology department of the 167 
Radboud University Medical Center, Nijmegen. Another 10 sporadic cases were recruited for 168 
participation by referring clinicians from the USA, France, United Kingdom and the 169 
Netherlands.   170 
 171 
Genetic testing 172 
DNA was extracted from blood samples and analyzed for D4Z4 repeat size, chromosome 4q 173 
and 10q haplotypes, as described previously6, and for SMCHD1 pathogenic variants by 174 
Sanger sequencing.1 CpG methylation at the D4Z4 repeat was determined by Southern blot 175 
and the methylation sensitive restriction enzyme FseI. Detailed protocols are freely available 176 
from the Fields Center website (www.urmc.rochester.edu/fields-center). The Delta1 score, a  177 
measure of the degree of D4Z4 hypomethylation, was calculated as described previously.7 178 
The Delta1 threshold for FSHD-associated SMCHD1 pathogenic variants lies below -21%.  179 
 180 
Clinical assessment 181 
All participants were interviewed regarding nasal and olfactory abnormalities, pubertal 182 
development, fertility, eye anatomy and vision, history of maxillofacial surgery, and presence 183 
of cleft lip/palate. Photographs were available for 10 participants, which were independently 184 
assessed by three clinicians.  185 
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In addition, ten members of one FSHD family were examined in person for (subtle) signs of 186 
arhinia or associated comorbidities by a clinical geneticist (MK) who was blinded to mutation 187 
status. Olfactory function was assessed using the Sniffin' Sticks Screening Test (Burghart, 188 
Medizintechnik, GmbH, Wedel, Germany) which assigns a sex and age-adjusted olfactory 189 
score. One family member was examined using Skype.  190 
 191 
Ethical approval  192 
This study was conducted according to the principles of the Declaration of Helsinki (version 193 
October 2013) and in accordance with the Medical Research Involving Human Subjects Act 194 
(WMO). Participants were consented under a protocol approved by the local ethics committee 195 
of the Radboud University Medical Center, Nijmegen. 196 
 197 
Data availability 198 
The data that support the findings of this study are available from the corresponding 199 
author upon reasonable request. 200 
 201 
Results 202 
Genetic results 203 
In the large Euro-Caucasian FSHD family, 8 family members carried a pathogenic missense 204 
variant in SMCHD1 (c.320T>C; p.Leu107Pro) (fig 1 and 2, table 1). Importantly this 205 
pathogenic variant was previously reported in an unrelated, African-American female with 206 
BAMS.2 All pathogenic variant carriers showed profound hypomethylation at the D4Z4 locus 207 
on chromosome 4q with Delta1 scores below -26%.7 The 5 affected individuals had the 208 
FSHD-permissive, 4qA haplotype that contains the somatic DUX4 PAS.6 In addition, four of 209 
them had a D4Z4 repeat array of 9 units, compatible with an additional molecular diagnosis of 210 
FSHD15, but also found in 1-2% of the Caucasian control population.8-10 The three unaffected 211 
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individuals were homozygous for the 4qB haplotype, which is not FSHD-permissive because 212 
of the absence of a somatic DUX4 PAS. One family member that tested negative for the 213 
SMCHD1 pathogenic variant, did carry a 9 unit repeat on a 4qA haplotype. Her Delta1 score 214 
was -9%.  215 
We identified 23 other sporadic FSHD2 patients in the FSHD genetic database with a 216 
pathogenic missense variantin close proximity to or identical to those previously identified in 217 
patients with arhinia or BAMS (2, 3, Shaw, unpublished observation). All FSHD2 patients had 218 
a permissive haplotype and D4Z4 hypomethylation (table 2). Seventeen of the 20 pathogenic 219 
variants in these FSHD2 patients involved the same SMCHD1 exon as in arhinia patients and 220 
three pathogenic variants were identical to those found in arhinia patients (figure 3). We also 221 
identified one family with a heterozygous 3-bp deletion in exon 6 (c.729_731delCTT; 222 
p.Phe244del) resulting in the deletion of a single amino acid just two positions downstream of 223 
an amino acid affected in BAMS patients. 224 
 225 
Clinical characteristics 226 
In the large FSHD family, six individuals with an N-terminal SMCHD1 pathogenic missense 227 
variant were examined (individuals II:1 and II:4 were deceased at the time of the study). None 228 
of them had microphthalmia, congenital cataracts, coloboma, nasolacrimal duct atresia, mid-229 
face hypoplasia, or cleft lip/palate (table 3). Several family members had narrow nares and/or 230 
hypoplastic alae nasi (rounded prominence of nostril) but these features did not segregate with 231 
the SMCHD1 pathogenic variant, suggesting they were unrelated, familial traits. One family 232 
member with FSHD1 and 2 (II-3) developed anosmia shortly after surgery for a deviated 233 
nasal septum. A second affected patient with both FSHD1 and 2 (III-3) was hyposmic 234 
(Sniffin' Sticks Screening Test result below the 10th percentile). All family members who 235 
were questioned reported normal pubertal timing and denied infertility.  236 
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Four family members had symptoms of FSHD: the two older individuals (50 years and older) 237 
displayed severe muscle weakness and were wheelchair-dependent, whereas the two younger 238 
individuals had facial weakness, an early sign of FSHD. Three of them had both FSHD1 and 239 
2, and one of the younger individuals only had FSHD1.  240 
The 10 sporadic FSHD2 patients who were phenotyped did not have physical features 241 
consistent with arhinia/BAMS (table 4). One male reported normal pubertal development but 242 
had infertility of unknown etiology. He denied other signs of hypogonadism such as 243 
cryptorchidism or micropenis and had never required testosterone replacement. Photographs 244 
of this patient revealed no signs of a craniofacial defect. 245 
 246 
Discussion 247 
We assessed FSHD patients with pathogenic missense variants in the N-terminal region of 248 
SMCHD1, which were recently shown to cause arhinia/BAMS, to determine whether FSHD2 249 
and BAMS might represent the opposite ends of one broad, phenotypic spectrum or if each 250 
condition is caused by SMCHD1 dysfunction in the presence of a genetic background unique 251 
to each condition. Only one patient with arhinia has been identified thus far who meets 252 
clinical and genetic criteria for FSHD22, and until now, FSHD2 patients had never been 253 
specifically assessed for BAMS-like features.  254 
Detailed examination of a large FSHD family with an SMCHD1 pathogenic variant identical 255 
to one found in BAMS patients did not uncover any congenital defects or dysmorphic features 256 
commonly found in patients with BAMS. We identified one patient in this family who 257 
developed cataracts in her 70’s and lost olfaction after nasal surgery. These findings are 258 
unlikely to be related to BAMS as cataracts are very common with aging secondary to 259 
cumulative photo-oxidative insults (e.g. ultraviolet-B) and she did not have congenital 260 
anosmia as occurs in BAMS patients; rather she lost olfactory function after nasal surgery 261 
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which is a recognized, albeit rare, potential side effect of septoplasty.11, 12 We also observed 262 
several family members with nasal hypoplasia. The power of our combined genetic and 263 
phenotypic approach, however, allowed us to confidently classify this phenotype as a familial 264 
rather than SMCHD1-related trait as it did not segregate with the SMCHD1 pathogenic 265 
variant.  266 
All other FSHD2 patients included in this study reported normal olfaction, no craniofacial or 267 
ocular abnormalities and normal pubertal development and those of reproductive age were 268 
fertile with the exception of one male patient with infertility of unknown cause. Thus, we find 269 
no evidence for phenotypic overlap in FSHD2 and BAMS patients. 270 
 The phenotyping protocol for this study was intentionally simple and non-invasive in design 271 
such that all study procedures could be performed by patients from afar. Although we 272 
performed detailed, structured interviews to collect phenotypic data on the sporadic cases, it is 273 
possible that patients were not fully aware of any subtle BAMS-associated features. Future 274 
studies will be required to confirm our findings in a larger number of FSHD patients using 275 
more sophisticated tools such brain imaging to assess the integrity of the olfactory bulbs and 276 
tracts, dilated eye exams, and reproductive hormone testing. 277 
Our data support the hypothesis that arhinia/BAMS and FSHD2 represent two distinct 278 
oligogenic disorders. In both conditions, SMCHD1 dysfunction appears to be necessary but 279 
not sufficient to cause disease. In FSHD2, a permissive 4q35 haplotype is one known 280 
requirement, but the variability in muscle weakness that is seen among family members with 281 
the same SMCHD1 pathogenic variant (and D4Z4 repeat size) suggests that there are other 282 
genetic or environmental modifiers yet to be discovered. Incomplete penetrance of SMCHD1 283 
variants in the form of nasal hypoplasia or isolated anosmia has also been observed in 284 
multiplex arhinia/BAMS families.2 Modifier genes have not been identified in arhinia but 285 
SMCHD1 binding partners and/or downstream targets are rational candidates. Thus, in the 286 
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extremely rare chance that a patient has an N-terminal SMCHD1 pathogenic variant and 287 
meets the genetic requirements unique to arhinia/BAMS and to FSHD2, he/she can 288 
demonstrate both conditions.       289 
Pathogenic variants in the N-terminal region of SMCHD1 play a critical role in the 290 
pathogenesis of both FSHD2 and arhinia/BAMS and. The complete absence of phenotypic 291 
overlap between these two disorders, however, suggests that these variants are, by themselves, 292 
insufficient to cause either disorder. The current study instead supports an oligogenic or 293 
multifactorial disease mechanism for both FSHD2 and arhinia/BAMS.  294 
 295 
 296 
  297 
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Tables 334 
Table 1. Genetic characteristics of FSHD family members. 335 
ID 
Fig 1 Sex Age 4q35 locus 
SMCHD1 variant and D4Z4 
methylation (%) 
At risk 
for FSHD 
      
4q_1 
units 
4q_1 
haplotype 
4q_2 
units 
4q_2 
haplotype 
FseI 
methylation 
Delta1 
methylation SMCHD1    
II-1 F † 20U 4B163 23U 4B163 3% -42% +/- No 
II-2 M 80y 27U 4A161 28U 4B163 58% 12% +/+ No 
II-3 F 75y 9U 4A161 20U 4B163 4% -33% +/- FSHD1+2 
II-4 M † 9U 4A161 20U 4B163 n/a n/a +/- FSHD1+2 
II-5 M † 20U 4B163 23U 4B163 25% -16% +/+ No 
III-1 F 52y 20U 4B163 28U 4B163 11% -34% +/- No 
III-2 M 61y 39U 4A161 45U 4B168 n/a n/a +/+ No 
III-3 F 51y 9U 4A161 27U 4A161 6% -35% +/- FSHD1+2 
III-4 M 47y 20U 4B163 28U 4B163 7% -39% +/- No 
IV-1 F 21y 18U 4B163 66U 4A161 22% -29% +/- No 
IV-2 F 18y 9U 4A161 45U 4B168 36% -9% +/+ FSHD1 
IV-3 M 16y 9U 4A161 39U 4A161 16% -26% +/- FSHD1+2 
IV-4 M 19y 28U 4B163 40U 4B168 52% 6% +/+ No 
IV-5 F 14y 20U 4B163 40U 4B168 47% 3% +/+ No 
 336 
M: male; F: female; n/a: not available; 4q_1 and 4q_2 represent the two alleles on 337 
chromosome 4q35; †: deceased; U: units. IDs correspond to those in the pedigree (Figure 1). 338 
  339 
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Table 2. Genetic characteristics of FSHD2 patients.  340 
ID          
Fig 3 Sex 4q35 locus SMCHD1 variant and D4Z4 methylation (%) 
    
4q_1 
units 
4q_1 
haplotype 
4q_2 
units 
4q_2 
haplotype 
FseI 
methy-
lation 
delta1 
methy- 
lation 
SMCHD1 cDNA 
(NM_015295.2)  
SMCHD1 
variant 
(NP_056110.2) 
Position relative to known 
BAMS mutation exon 
2   see Table 1 see Table 1 c.320T>C p.Leu107Pro identical to p.Leu107Pro 3 
7 M 13 A 33 B 12 -28 c.580C>T p.Leu194Phe 23 aa distal to p.Phe171Val 5 
8 M 11 A 39 B 5 -33 c.610A>G p.Lys204Glu 33 aa distal to p.Phe171Val 5 
10a M no genotype data (no DNA) 3 n/a c.729_731delCTT p.Phe244del  2 aa distal to p.Ala242Gly 6 
10b F no genotype data (no DNA) NA n/a c.729_731delCTT p.Phe244del  2 aa distal to p.Ala242Gly 6 
10c M no genotype data (no DNA) NA n/a c.729_731delCTT p.Phe244del  2 aa distal to p.Ala242Gly 6 
12 F 13 A n/a n/a 5 n/a c.848A>G  p.Tyr283Cys 41 aa distal to p.Ala242Gly 7 
14 M 17 A 47 A 9 -41 c.1058A>G p.Tyr353Cys 5 aa distal to p.His348Arg 9 
15 F 14 A 15 A 1 -37 c.1273G>A p.Gly425Arg 5 aa distal to p.Asp420Val 10 
18 M 11 A 35 B 7 -29 c.1474T>C p.Cys492Arg 19 aa distal to p.Glu473Gln 12 
19 F 17 A 18 A 11 -31 c.1556T>C p.Phe519Ser 1 aa distal to p.Lys518Glu 12 
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M: male; F: female; n/a: not available; nl: normal; 4q_1 and 4q_2 represent the two alleles on chromosome 4q35. IDs correspond to the mutation 341 
number in Figure 3. 342 
  343 
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Table 3. Clinical findings in FSHD family with a pathogenic SMCHD1 variant. 344 
ID 
Fig 1  
Sex Age (y) SMCHD1 
variant 
Signs of FSHD Interview and assessment of dysmorphic features Pubertal 
development 
Sniffin’ 
sticks test 
Other 
II-1 F † +/- n/a (not at risk) n/a n/a n/a  
II-2 M 80 +/+ n/a (not at risk) n/a nl;  fertile n/a  
II-3 F 75 +/- severe FSHD, 
wheelchair 
bound 
narrow nares; high nasal bride; hypoplastic alae nasi; 
bilateral cataracts at age 73y; dystopia canthorum; 
elongated philtrum 
nl; fertile anosmia 
 
anosmia after nasal 
septum surgery 
II-4 M † +/- severe FSHD, 
wheelchair 
bound  
n/a n/a n/a  
II-5 M † +/+ n/a (not at risk) narrow nares; hypoplastic alae nasi nl n/a assessment using 
photographs 
III-1 F 52 +/- nl (not at risk) hypoplastic alae nasi; unilateral epicanthal fold; glasses 
(-0.25 and -4.25) 
nl; fertile n/a assessment using 
Skype 
III-3 F 51 +/- severe FSHD, 
able to walk a 
narrow nares and nose; high nasal bridge; hypoplastic 
and asymmetrical alae nasi; micrognatia 
nl; fertile hyposmia   
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few steps with 
support  
III-4 M 47 +/- nl (not at risk) high nasal bridge; asymmetrical alae nasi; long 
philtrum 
nl; fertile normosmia  
IV-1 F 21 +/- nl (not at risk) asymmetrical alae nasi nl normosmia  
IV-2 F 18 +/+ mild facial 
weakness 
tendency to hypertelorism; short philtrum nl normosmia  
IV-3 M 16 +/- facial weakness coarse facial features; thick and asymmetrical alae nasi; 
strabism; tendency to hypertelorism; retrognatia 
nl normosmia mild learning 
disability 
IV-4 M 19 +/+ nl (not at risk) none nl normosmia  
IV-5 F 14 +/+ nl (not at risk) midline raphe nl normosmia  
F: female; M: male; †: deceased; y: years; n/a: not available; nl: normal. IDs correspond to those in the pedigree (Figure 1). 345 
 346 
  347 
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Table 4. Clinical findings in sporadic FSHD2 patients as determined by interview and photographs 348 
ID  
Fig 3 
Sex BAMS-associated phenotypes Photographs 
    Smell Nasal 
abnormalities 
Nasal 
surgery  
Open 
nostrils 
Vision Eye 
anatomical 
abnormalities 
Tear 
production 
Pubertal 
development 
Fertility Cleft 
lip/ 
palate 
  
7 M nl no no yes nl no nl nl nl no n/a 
8 M nl no adenoid 
removal 
yes glasses no nl nl nl no n/a 
10a M nl no no yes Astigmatism, 
hypermetropy 
no nl nl nl no n/a 
10b F nl no no yes nl no nl nl nl no n/a 
10c M nl no no yes nl no nl nl nl no n/a 
12 F nl no no yes nl no nl n/a n/a no n/a 
14 M nl Difficulty 
clearing 
secretions 
no yes glasses no Decreased 
(Schirmer's 
test score 
4) 
Decreased 
body hair 
Infertile no no abnormalities 
15 F nl no no yes nl no nl nl nl no n/a 
18 M nl no no yes nl no nl nl nl no n/a 
19 F nl no no yes glasses no nl nl nl no no abnormalities 
n/a: not available; nl: normal. IDs correspond to the mutation number in Figure 3. 349 
    350 
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Figures legends 351 
Figure 1. Pedigree for FSHD2 multiplex family with pathogenic variant (p.L107P) in 352 
SMCHD1. Shaded symbols represent family members meeting clinical criteria for FSHD2. 353 
Genetic information is listed below each family member: top box is mutation status 354 
(SMCHD1 variant present or WT- wild type), lower boxes indicate the 4q35 haplotype (A or 355 
B) and D4Z4 repeat length (units) for each allele. 356 
 357 
Figure 2. Sequence track of the SMCHD1 pathogenic variant in the FSHD2 family and in a 358 
control sample. The position of the variant in exon 3 is indicated above the sequence traces 359 
and is highlighted in yellow. The genomic position is based on reference genome hg19 and 360 
the transcript and protein position on accession number NM015295 and NP056110, 361 
respectively. 362 
 363 
Figure 3. Schematic of pathogenic missense variants in the N-terminal region of SMCHD1 364 
associated with FSHD2 and/or arhinia/BAMS. Pathogenic variants in the FSHD2 cohort in 365 
the current study are in bold (see also table 2), and the pathogenic variants that have been 366 
implicated in both FSHD2 and BAMS are underlined. 367 
 368 



